Comparison · NCT00762034-cbac68df
Pem/Carbo/Bev vs Pac/Carbo/Bev: Number of Participants Who Received a Transfusion
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pem/Carbo/Bev vs Pac/Carbo/Bev: Number of Participants Who Received a Transfusion. Trial comparisons, record NCT00762034-cbac68df. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00762034-cbac68df
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.262 | 0.224 | 0.305 | wilson | |
| Risk in group 2 | 0.0993 | 0.0748 | 0.131 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | 0.113 | 0.213 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.64 | 1.92 | 3.64 | log | |
| Odds ratio, group 1 over group 2 | 3.23 | 2.21 | 4.7 | log | |
| Number needed to treat, for one more participant with the outcome on Pem/Carbo/Bev than on Pac/Carbo/Bev | 6.13 | 4.7 | 8.84 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pem/Carbo/Bev | Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab~Bevacizumab: Induction therapy 15 milligrams per kilogram (mg/kg) intravenously (IV) every 21 days for up to 4 cycles of 21 days~Bevacizumab: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.~Pemetrexed: Induction therapy 500 milligram per meter squared (mg/m\^2) IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days~Pemetrexed: Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation~Carboplatin: Induction therapy of 6 area under the concentration curve (AUC 6) IV every 21 days for up to 4 cycles of 21 days | 116 | 442 | OG000 |
| Group 2 | Pac/Carbo/Bev | Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab~Paclitaxel: Induction therapy 200 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days~Bevacizumab: Induction therapy 15 mg/kg IV every 21 days for up to 4 cycles of 21 days~Bevacizumab: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.~Carboplatin: Induction therapy 6 area under the concentration curve (AUC 6) IV every 21 days for up to 4 cycles of 21 days | 44 | 443 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Received a Transfusion
- Description
- Time frame
- Baseline to study endpoint (up to 37.06 months)
- Population
- All randomized participants who received at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
- NCT number
- NCT00762034
- Phases
- PHASE3
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pemetrexed, Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab, Bevacizumab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2013-11-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00762034?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00762034-cbac68df